European Pharmaceutical Review
JULY 18, 2023
According to the research, the pharmaceutical quality management systems market is projected to reach $3.97 billion by 2030. Some pharmaceutical companies are increasing their R&D spending to increase product numbers. Also noted in the report was the shift towards cloud-based systems.
European Pharmaceutical Review
AUGUST 17, 2022
billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 Pharmaceutical companies globally are significantly investing in R&D. percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. percent from its 2022 value of $35.1
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 7, 2022
billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 The rising requirement for small-scale and encapsulated manufacturing processes necessary to assemble these products make it challenging for many pharmaceutical companies to alter their currently installed capacity.
The Guardian - Pharmaceutical Industry
NOVEMBER 12, 2024
The profit figure beat forecasts and the UK pharmaceutical company raised its guidance for growth in full-year revenues and earnings from “mid-teens” to “high teens”. It all sounded like another confident step in the march to take global revenues from $46bn in 2023 to $80bn by 2030. Continue reading.
European Pharmaceutical Review
APRIL 3, 2024
Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. percent between 2022-2030. The report noted that there has been “considerable” merger and acquisition activity in recent years within the pharmaceutical contract manufacturing market.
European Pharmaceutical Review
SEPTEMBER 12, 2023
Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development , within the next 24-months.
European Pharmaceutical Review
JULY 5, 2022
In the same statement, Pfizer also announced it has signed a pledge by the US Department of Health and Human Services (HHS) that calls on US healthcare system stakeholders such as hospitals, health systems, payers, suppliers and pharmaceutical companies to reduce GHG emissions and build a more climate resilient healthcare infrastructure.
Expert insights. Personalized for you.
98 
Let's personalize your content